Icosavax, Inc (ICVX) Prices 12.13M Share IPO at $15/sh

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the pricing of its upsized initial public offering of 12,133,333 shares of common stock at an initial public offering price of $15.00 per share. All of the shares are being offered by Icosavax. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Icosavax, are expected to be approximately $182.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on July 29, 2021 under the ticker symbol “ICVX.” The offering is expected to close on August 2, 2021, subject to the satisfaction of customary closing conditions. In addition, Icosavax has granted the underwriters a 30-day option to purchase up to an additional 1,819,999 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Jefferies, Cowen, Evercore ISI and William Blair are acting as joint book-running managers for the offering.

Registration statements relating to the offering have been filed with the Securities and Exchange Commission and became effective on July 28, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at [email protected] or by telephone at 877-821-7388; from Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] or by telephone at 833-297-2926; from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by email at [email protected] or by telephone at 888-474-0200; or from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by email at [email protected] or by telephone at 800-621-0687.

You May Also Be Interested In

• Suja Life refinances credit agreement, cuts borrowing spread
• Werewolf Therapeutics sells platform assets to EMD Serono for $33M
• QNB Corp. overallotment option adds 160,714 shares at $42 each